Learn more about open clinical trials for your Castleman disease patients.
As part of our mission to improve care and survival of patients with Castleman disease, the CDCN aims to support and educate the community about Castleman disease clinical trials and facilitate the research that forms the basis for clinical trials.
There are currently two open clinical trials for Castleman disease—one in the United States and one in China.
Sirolimus clinical trial, USA
The first USA clinical trial for a new Castleman disease treatment since 2012 is now open! The University of Pennsylvania and the University of Arkansas for Medical Sciences launched a clinical trial to evaluate the medication sirolimus. The trial is open for idiopathic multicentric Castleman disease patients that did not sufficiently get better with, or relapsed on, anti-IL6 treatment (siltuximab or tocilizumab). The trial has been posted to the federal registry for all clinical trials, found here. Patients can learn more about this trial at cdcn.org/trial. Please email CDtrial@pennmedicine.upenn.edu for more information.
BCD regimen clinical trial, China
The Peking Union Medical College Hospital in Beijing, China is currently recruiting for a clinical trial that is exploring the effectiveness and safety of the medications bortezomib, cyclophosphamide and dexamethasone (BCD regimen). The trial is open for patients who are newly diagnosed idiopathic multicentric Castleman disease. More information about this trial can be found here.
Siltuximab Clinical Trial, USA
A new clinical trial has opened for patients with idiopathic multicentric Castleman disease (iMCD), including iMCD-Thrombocytopenia/Anasarca/ Fever/Reticulin fibrosis/Organomegaly (TAFRO), in the United States (US).
EUSA Pharma will be conducting a research study of the approved medicine, siltuximab (Sylvant®), for adults and adolescents whose idiopathic multicentric Castleman disease (iMCD) has progressed on standard-dose siltuximab. Dr. Luis Fayad, MD Anderson Cancer Center, and Dr. Gordan Srkalovic, Sparrow Herbert-Herman Cancer Center are the Lead Principal Investigators for this study. Trial patients also need to have signs or symptoms of Castleman disease, including elevated and rising C-reactive protein (CRP) levels potentially indicative of excess circulating interleukin-6 (IL-6) that could use higher doses of siltuximab for more complete binding and neutralization. Participation in this study is entirely voluntary.